Protective Efficacy of a *Plasmodium vivax* Circumsporozoite Protein-Based Vaccine in *Aotus nancymaeae* Is Associated with Antibodies to the Repeat Region

Anjali Yadava¹, Cysha E. Hall¹, JoAnn S. Sullivan², Douglas Nace², Tyrone Williams², William E. Collins²†, Christian F. Ockenhouse¹, John W. Barnwell²

1 Malaria Vaccine Branch, Military Malaria Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America, 2 Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

**Abstract**

We have previously reported that Vivax Malaria Protein 001 (VMP001), a vaccine candidate based on the circumsporozoite protein of *Plasmodium vivax*, is immunogenic in mice and rhesus monkeys in the presence of various adjuvants. In the present study, we evaluated the immunogenicity and efficacy of VMP001 formulated with a TLR9 agonist in a water-in-oil emulsion. Following immunization, the vaccine efficacy was assessed by challenging *Aotus nancymaeae* monkeys with *P. vivax* sporozoites. Monkeys from both the low- and high-dose vaccine groups generated strong humoral immune responses to the vaccine (peak median titers of 291,622), and its subunits (peak median titers to the N-term, central repeat and C-term regions of 22,188; 66,120 and 179,947, respectively). 66.7% of vaccinated monkeys demonstrated sterile protection following challenge. Protection was associated with antibodies directed against the central repeat region. The protected monkeys had a median anti-repeat titer of 97,841 compared to 14,822 in the non-protected monkeys. This is the first report demonstrating *P. vivax* CSP vaccine-induced protection of *Aotus* monkeys challenged with *P. vivax* sporozoites.

---

**Introduction**

The range of *Plasmodium vivax* transmission spans 95 countries putting 2.86 billion people at risk for this malaria parasite [1] and causes an estimated 132–391 million infections each year [2]. In addition to its widespread distribution, *P. vivax* also has the propensity to form dormant hypnozoites in the liver, which reactivate periodically and result in recurring relapse infections. Currently, the only treatment for these intrahepatic hypnozoites is the 8-aminoquinoline, primaquine (PQ), which is contraindicated in a variable proportion of populations due to a risk of hemolysis in individuals with G6PD deficiency [3] or during pregnancy. More recently, Bennett and colleagues reported an association between decreased activity of the CYP2D6 isoenzyme and reduced metabolism of PQ resulting in treatment failure [4]. This further reduces the pool of individuals who may be treated with PQ, reinforcing the need to develop a vaccine to prevent *P. vivax* malaria. However, resources for vivax research remain limited, with only 5% of malaria funds specifically directed toward *P. vivax* between 2007 and 2011 (PATH Malaria R&D Report, 2013). In addition, funding initiatives such as the U.S. government’s President’s Malaria Initiative (PMI) have strictly limited assistance, mostly to select countries in Africa, leaving little room for funding vivax malaria control or research [5].

Due to the unpredictability of hypnozoite reactivations that cause relapse infections, an intervention based on a preerythrocytic stage antigen is even more imperative for *P. vivax* to prevent primary infection and subsequent relapse infections. The circumsporozoite protein (CSP) is the major protein present on the surface of sporozoites and is involved in hepatocyte binding and invasion and as such is the lead vaccine candidate for malaria. Presence of CSP on hypnozoites [6] makes it an attractive target against both the sporozoite, and intrahepatic parasites. We have designed and produced a vaccine based on the CSP of *P. vivax* and demonstrated its antigenicity and immunogenicity [7] [8].

Rodents serve as a platform for the initial screening of malaria vaccine candidates. However, non-human primates, being closer to humans, are more suitable models to assess vaccines. A limited
Author Summary

*Plasmodium vivax* is responsible for causing malaria in large parts of the globe, including regions with temperate climates not suited for the transmission of other *Plasmodium* species. In addition, *P. vivax* has the propensity to form dormant forms, known as hypnozoites, that can remain latent for weeks to months and reactive periodically to cause recurrent infections. Prevention of *P. vivax* malaria, more than any other form, will require a vaccine-based intervention due to limitations in treatment options. To this end, we tested the efficacy in non-human primates, of a vaccine based on circumsporozoite protein, a preerythrocytic stage antigen, of *P. vivax*. *Aotus* monkeys were immunized with clinical-grade antigen, combined with two immunomodulators, and then challenged with *P. vivax* sporozoites. Following challenge 66.7% of monkeys were protected. Analysis of serum samples indicated that protection was associated with antibodies to the central repeat region of the molecule, and that protection was lost upon waning of these antibodies. This is the first report demonstrating that active immunization with a recombinant protein can lead to complete protection in monkeys following sporozoite challenge, while also demonstrating a protective associate. Our data can help serve as a benchmark for down-selection of future vaccine formulations for *P. vivax*.

number of studies have been performed to analyze immunogenicity, and even fewer to assess the efficacy, of candidate vaccines for *P. vivax* in non-human primates. In the late 1980s and early 1990s studies were performed with recombinant *P. vivax* CS proteins produced in yeast [9] and *E. coli* (WRAIR-SKB), which gave little to no protection in immunized *Saimiri* monkeys [10]. Subsequently, multiple antigen constructs were used to develop epitope-based vaccines using the vivax repeat motif. Protection was observed in *Saimiri* monkeys [11] [12], but the lack of a control group makes it difficult to conclusively interpret the data in these studies. An *Aotus* monkey model was used to assess immunogenicity of CS multiple antigen peptides (MAP) and long synthetic peptides (LSP) and cells from immunized monkeys were used to delineate T-cell epitopes on the protein [13] [14]. No challenge studies were performed with the MAP or LSP immunized monkeys to correlate the immunogenicity to protection.

In this study, we evaluated the immunogenicity and protective efficacy of VMP001, a soluble *P. vivax* CSP-based vaccine, co-formulated with a TLR-9 agonist and a water-in-oil emulsion. Immunized *A. nancymaae* monkeys demonstrated high antibody titers and high efficacy following challenge with *P. vivax* sporozoites. Vaccine efficacy was shown to be associated with antibodies to the repeat region of *P. vivax* CSP. To our knowledge, this is the first report of an efficacy study of a recombinant CSP-based vaccine in *Aotus nancymaae* monkeys, and the first to conclusively correlate this protection to antibodies generated against the repeat region of the CSP following immunization.

Materials and Methods

### Immunogens and antigens

The vaccine antigen, designated Vivax Malaria Protein 001 (VMP001), is based on the *P. vivax* CSP and has been described previously [7,8]. Briefly, the gene encoding a chimeric central repeat region containing the nonamer repeat motifs from both *PvCSP* and *LSA-1* were produced in yeast [9] and *E. coli* (WRAIR-SKB), which gave little to no protection in immunized *Saimiri* monkeys [10]. Subsequently, multiple antigen constructs were used to develop epitope-based vaccines using the vivax repeat motif. Protection was observed in *Saimiri* monkeys [11] [12], but the lack of a control group makes it difficult to conclusively interpret the data in these studies. An *Aotus* monkey model was used to assess immunogenicity of CS multiple antigen peptides (MAP) and long synthetic peptides (LSP) and cells from immunized monkeys were used to delineate T-cell epitopes on the protein [13] [14]. No challenge studies were performed with the MAP or LSP immunized monkeys to correlate the immunogenicity to protection.

In this study, we evaluated the immunogenicity and protective efficacy of VMP001, a soluble *P. vivax* CSP-based vaccine, co-formulated with a TLR-9 agonist and a water-in-oil emulsion. Immunized *A. nancymaae* monkeys demonstrated high antibody titers and high efficacy following challenge with *P. vivax* sporozoites. Vaccine efficacy was shown to be associated with antibodies to the repeat region of *P. vivax* CSP. To our knowledge, this is the first report of an efficacy study of a recombinant CSP-based vaccine in *Aotus nancymaae* monkeys, and the first to conclusively correlate this protection to antibodies generated against the repeat region of the CSP following immunization.

### Immunizations and bleeds

Male and female monkeys were randomly assigned to three groups of eight animals each. Two test groups received either 15 μg or 50 μg of VMP001 per immunization. A third group of monkeys, which served as controls, was immunized with 30 μg *P. falciparum* LSA-1. All antigens were formulated in Montanide ISA 720 (Seppic, NJ) (antigen to adjuvant ratio of 30:70) plus 200 μg of CpG 10104 (Coley Pharma) per immunization. Animals were immunized intramuscularly in the thigh muscles, alternating legs for each immunization, with approximately 300 μl of each...
vaccine formulation on day 0, 28 and 114. Monkeys were bled two weeks prior to immunization and at two-week intervals following vaccinations for the collection of serum. Serum was separated by centrifugation, aliquoted and frozen at −70°C until use.

**Challenge**

Sporozoites were isolated from salivary glands of *Anopheles dirus* that were infected with the Brazil VII strain of *P. vivax* after feeding on an infected *A. lemurinus grisemembra* monkey.

---

*Figure 1. Aotus nancymaae immunized with VMP001 generated antigen-specific antibodies that were boosted following each immunization.* Groups of 8 monkeys were immunized three times with either 15 µg (panel A) or 50 µg (panel B) of VMP001 formulated with 200 µg CpG 10104 and Montanide ISA 720. Sera, drawn at two week intervals, were tested for presence of antibodies to VMP001. Antibody titers waned over time, but were boosted with each immunization. Titers are defined as serum dilution that gives an OD$_{414}$ of 1.0. Each symbol represents an individual monkey. Some time points have less than eight data points due to the unavailability of serum sample at that time point. Horizontal bars represent the median titer for each group at the given time point. 

DOI:10.1371/journal.pntd.0003268.g001
The Brazil VII strain of *P. vivax* carries a type I (VK210) csp gene (J. Barnwell, unpublished data). Each monkey was challenged intravenously with 10,000 sporozoites six weeks after the third immunization. Two to three days following sporozoite challenge all the monkeys were splenectomized under general anesthesia and sterile operating conditions. Splenectomies were performed to allow for the establishment of a synchronous blood stage infection resulting in a more uniform, and shorter, prepatent period.

Blood stage parasitemia was monitored in thick and thin Giemsa stained blood smears starting approximately 14 days post-challenge. Monkeys that demonstrated patent blood stage infection were treated with 50 mg/kg of quinine for seven days. Parasitemia was monitored on a daily basis until the conclusion of second phase of the study (described below).

Kaplan-Meier survival curves were generated for each group individually, as well as for pooled (low- and high-dose) vaccinated groups, and plotted as percentage of uninfected monkeys over time. Survival curve comparisons were performed using Log-rank (Mantel-Cox) test. Overall vaccine efficacy (VE) was calculated as 1-R where R = Iv/Ic i.e. the ratio of Incidence of malaria in vaccinated group (Iv) to the Incidence of malaria in the control group (Ic).

At eight weeks post primary challenge all surviving monkeys were rechallenged intravenously with a higher dose of 15,000 *P. vivax* Brazil VII sporozoites. Monkeys that demonstrated patent blood infection were treated with quinine as above.

**ELISAs**

Sera from monkeys were tested for the presence of CSP antibodies following immunization. Immulon 2HB plates (Dynatech, VA) were coated with 0.4 µg/ml VMP001, N- and C-terminal regions of *P. vivax* CSP or 1 µg/ml of Type 1 peptide. Sera from a selected time point were also screened against *PfLSA1* to determine if the control group generated antibodies against the transgene, and to ensure that there was no cross reactivity between the control and vaccine groups. Plates were blocked, incubated with serially diluted serum, followed by 1:6000 dilution of a custom prepared goat anti-*Aotus* IgG (CDC, Atlanta) labeled with horseradish peroxidase (HRP). The reaction was developed with ABTS and read after 60 min at A414. ELISA titers are defined as the serum dilution that gives an optical density (OD414) of 1.0.

**Statistical analysis**

GraphPad Prism version 5.0 was used for statistical analysis. Tests used for each analysis are mentioned along with the corresponding data.

**Results**

**Immunogenicity of VMP001 vaccine in *Aotus* – Analysis of anti-VMP001 antibodies**

Monkeys were immunized with either 15 µg (low dose) or 50 µg (high dose) of VMP001 formulated with Montanide ISA 720 in combination with 200 µg of CpG 10104, a TLR-9 agonist. This study was designed with an ultimate goal of assessing the efficacy of the VMP001 vaccine formulation. Adjuvants are known to induce innate immune responses which can affect the outcome of a challenge. Therefore, in order to rule out the role of non-specific immune responses we immunized a group of monkeys with *P. vivax*.
falciparum LSA-1 that served as an unrelated malaria antigen, formulated in adjuvant. Monkeys were immunized three times, with a one month interval between the 1st and 2nd immunization, and a three month interval between the 2nd and 3rd immunizations. Animals were monitored following each immunization and no reactogenicity or adverse events were observed. None of the control monkeys that received PfLSA-1 generated any antibodies against VMP001 following immunization, however, robust anti-PfLSA1 responses were detected in this group, while none of the VMP001 immunized sera showed any anti-PfLSA1 reactivity (data not shown). Anti-VMP001 antibodies were detected in all monkeys immunized with VMP001 two weeks following the 1st immunization (Figure 1). The median titers at 2 weeks post 1st immunization were 14,581 and 67,695 for the low and high dose.

**Figure 3.** Protective efficacy of VMP001 in *Aotus* monkeys challenged intravenously with *P. vivax Brazil VII* strain post primary and rechallenge. Monkeys were immunized with either 15 μg or 50 μg of VMP001. Control monkeys were immunized with 50 μg of *P. falciparum* LSA-1 (PfLSA-1). All antigens were formulated with Montanide ISA 720 and CpG 10104. Kaplan-Meier survival curves represent percentage of uninfected monkeys over time. Vaccine Efficacy was calculated as a ratio between the vaccinated and control groups (see results). 3A. Six weeks following the third immunization, all monkeys were challenged intravenously with 10,000 *P. vivax Brazil VII* parasites. 3B. Eight weeks after the primary challenge, monkeys were rechallenged with 15,000 *P. vivax Brazil VII* parasites.

doi:10.1371/journal.pntd.0003268.g003
groups, respectively. These titers were boosted significantly at 2 weeks post 2nd immunization for both the low dose (144,302; \( p = .02 \)) and high dose (198,024; \( p = .02 \)) groups. Antibody titers declined over time and the titers were significantly lower in both immunized groups at 12 weeks after the 2nd immunization compared to the peak titers obtained two weeks after the 2nd immunization (\( p = .0006 \) and \( p = .015 \) for the low and high dose groups, respectively). Titers showed a boost following the 3rd immunization and peaked 4 weeks post 3rd immunization. There was a significant difference between the titers at 12 weeks post 2nd immunization (28,940) and 4 weeks post 3rd immunization (140,367; \( p = .005 \) for the low dose group and the high dose group (78,163 at 12 weeks post 2nd immunization and 291,622 at 4 weeks post-3rd immunization; \( p = .005 \)). The peak titers post the 2nd and 3rd immunizations were not significantly different (Figure 1).

The antibody titers for both the low and high dose groups were similar at 2 weeks post each immunization (Figure 2). The median titers ranged from a low of 14,581 at 2 weeks post 1st immunization for the low dose group, to a high of 198,024 for the high dose group at 2 weeks post 2nd immunization. There were no statistical differences in antibody titers between the groups at each time point indicating that a strong adjuvant overcomes antigen dose effects.

Efficacy of VMP001 following intravenous challenge with \( P. \) vivax Brazil VII parasites

Following intravenous inoculation of sporozoites, six of the eight \( P. \) vivax control monkeys became parasitemic, with a tight pre-patent period ranging from day 14 to 18 post-challenge (Figure 3A). In fact, five of the six infected monkeys had demonstrated patent infection by day 16. The remaining monkey became positive on day 18. Six of the eight monkeys in each of the two vaccinated groups did not demonstrate patent infection. In both the low and high dose groups 25% monkeys in each group (2/8) became parasitemic with a pre-patent period (day 17 and 28 for the low dose group; day 16 and 17 for the high dose group) that was delayed in one animal compared to the controls. The median prepatent period for the control group was 15.5 days, 22.5 days for the low dose group and 16.5 days for the high dose group. Total vaccine efficacy, calculated by comparing the ratio of infected monkeys in the vaccinated vs. the control group, for each group was 66.7%; and the \( p \) values, based on the Mantel-Cox Log-rank test, for the time to parasitemia were .02 and .03 for the low and high dose groups respectively.

Following treatment, all surviving monkeys were rechallenged intravenously eight weeks post primary challenge with a higher dose of 15,000 \( P. \) vivax Brazil VII sporozoites. This allowed for an
Protective efficacy of PvCSP in Aotus

Non-protected

|       | N-term | Repeat | C-term | VMP001 |
|-------|--------|--------|--------|--------|
| N-term| ns     |        |        |        |
| Repeat|        |        |        | 0.034  |
| C-term|        |        |        |        |
| VMP001|        |        |        |        |
approximately two-week interval between the clearance of any primary infections before the rechallenge. Seven of seven control monkeys became parasitemic between days 11 and 15 (Median day 13) (Figure 3B). Six of six challenged monkeys in the high dose group became parasitemic between days 12 and 22 (Median day 14.5) and seven of eight of the low dose group became parasitemic between day 12 and 18 (Median day 13.5). One monkey in the low dose group did not become parasitemic during the 33 day post-rechallenge observation period.

Induction of anti-VMP001 antibodies following challenge with *P. vivax* sporozoites

As expected, the control animals, immunized with an unrelated malaria antigen, PfLSA-1, did not induce antibodies to VMP001 (Figure 4) after the 3rd immunization. However, following primary challenge, these animals generated antibodies to CSP, as demonstrated by the presence of antibodies to VMP001 (Median titer: 797). The titters were boosted approximately 10-fold following rechallenge to a median titer of 7,670. The differences between the prechallenge and postchallenge anti-PvCSP (VMP001) titers in the PfLSA-1 group were statistically significant (Figure 4). Since the prechallenge anti-VMP001 titers in the vaccinated monkeys were already high, the differences in titers post-challenge were not significant.

Immunogenicity of VMP001-antibody fine-specificity analysis

Serum from immunized monkeys was further analyzed to assess the breadth of antibody responses generated. At 4 weeks post 3rd immunization (2 weeks pre-challenge) all monkeys demonstrated presence of antibodies to the N-, Central Repeat as well as the C-terminal region of *P. vivax* CSP. As with VMP001 (Median titers of 140,367 and 291,622 for the low and high dose groups respectively) there was no significant difference between the antibody titers against the N-term (Median 7,277 vs. 22,188), Type 1 repeat peptide (Median 66,120 vs. 25,297) and C-term regions (Median 214,659 vs. 156,247), N-term (Median 14,979 vs. 202,126) titers. The vaccine induced potent humoral responses in oil (GLA-SE), we demonstrated the safety and immunogenicity of VMP001. The vaccine induced potent humoral responses directed to the different regions of the molecule, and a cellular response predominantly directed to the C-terminal region of the protein [18]. In another study, rhesus monkeys were immunized with soluble recombinant protein (VMP001), as well as its particulate counterpart CSV-S,S which is a fusion between VMP001 and the hepatitis B surface antigen to compare the immunogenicity of the two formulations in AS01, an adjuvant approved for human use [19]. Both the soluble and particulate vaccines induced strong humoral and cellular immune responses, but with some qualitative and quantitative differences between the two formulations.

Association between anti-Type 1 antibody levels and vaccine efficacy

The data was reanalyzed by pooling the protected (n = 12) and non-protected (n = 4) monkeys from both the high and low dose groups (Figure 5). There were no statistical differences between the VMP001 (Median 214,659 vs. 156,247), N-term (Median 14,979 vs. 11,952) and C-term (Median 116,291 vs. 202,126) titers. The titers to the Type 1 repeat peptide were significantly different between the protected (Median 97,841) and non-protected (Median 214,569) groups (p = 0.03; 2-tailed Mann Whitney U test), indicating that high anti-repeat antibodies may be a correlate of protection. This is in accordance with data from *P. falciparum* vaccine studies where anti-repeat antibodies have been shown to be the strongest correlate of protection in humans [16]. As stated earlier, all but one of the vaccinated monkeys that were protected following primary challenge (Figure 6A) lost their protection upon rechallenge (Figure 6B). Nevertheless, when data from the low- and high-dose groups were combined following rechallenge and compared to the controls, there was still a significant difference between the immunized and control groups (p = 0.036) (Figure 6B). In comparison, following primary challenge the combined vaccinated groups had a p-value of 0.004 compared to the controls (Figure 6A).

We therefore compared the antibody titers in the prechallenge sera from the monkeys that were protected prior to the primary challenge to the titers in sera from those that were not protected following rechallenge. Sera were drawn two weeks before the primary-, or re-challenge. Here too, the only significant differences were found between the anti-repeat antibodies. As shown in Figure 6C the median anti-Type 1 repeat antibody titer in the protected monkeys was 97,841 at the time of primary challenge compared to 14,822 (p = 0.02) in the monkeys that were not protected following rechallenge. Thus, the loss of protection in the previously protected monkeys could be attributed to waning of the anti-repeat antibodies. Antibodies to VMP001 also declined (Median 214,569 vs. 97,296) but the decrease was not statistically significant. There was no association between antibody titers and time to patency in the monkeys that became parasitemic.

Discussion

Due to financial, logistical, and scientific challenges, efforts to develop vaccines for *P. vivax* have been disproportionately slower compared to that for *P. falciparum*. In addition to the limited number of preclinical studies in non-human primates that we describe above, a recent review by Reyes-Sandoval and Bachman [17] highlights the meager clinical portfolio of *P. vivax* vaccines and the current status of vivax research and funding. In sharp contrast to *P. falciparum*, so far, only one efficacy study has been conducted in humans (clinical trials registration number NCT01157997, Bennett et. al. in preparation). There is a need to test products to down-select candidate(s) that can be advanced to the clinic.

Towards this end, we produced a recombinant CSP-based vaccine and assessed its immunogenicity in rhesus monkeys using two different TLR4 agonists as adjuvants. In a study using a synthetic TLR4 agonist, glycyrophysosyl lipid A (GLA), formulated in oil (GLA-SE), we demonstrated the safety and immunogenicity of VMP001. The vaccine induced potent humoral responses directed to the different regions of the molecule, and a cellular response predominantly directed to the C-terminal region of the protein [18]. In another study, rhesus monkeys were immunized with soluble recombinant protein (VMP001), as well as its particulate counterpart CSV-S,S which is a fusion between VMP001 and the hepatitis B surface antigen to compare the immunogenicity of the two formulations in AS01, an adjuvant approved for human use [19]. Both the soluble and particulate vaccines induced strong humoral and cellular immune responses, but with some qualitative and quantitative differences between the two formulations.
Figure 6. Loss of protective efficacy following rechallenge could be attributed to a drop in anti-repeat antibody titers. Kaplan-Meier survival curves were generated by pooling data from the low (15 μg) and high (50 μg) dose groups (from Figure 3), and the combined VMP001 immunized group was compared to the control group. 6A. Following primary challenge, 12 of 16 immunized monkeys and 2 of 8 control monkeys remained uninfected, resulting in a calculated vaccine efficacy of 66.7% (p = 0.004). 6B. Following rechallenge, one immunized monkey remained uninfected and several others had a delay compared to the controls (p = .04). 6C. Sera drawn two weeks prior to the first challenge from protected monkeys (n = 12) had significantly higher anti-repeat antibody titers compared to sera drawn pre-rechallenge from the non-protected monkeys (n = 13); p = 0.02 (2-tailed Mann Whitney U-test). Titers indicate serum dilution that gives an OD414 of 1.0. Each dot represents an individual monkey. Horizontal bar represents the median titer for each group.

doi:10.1371/journal.pntd.0003268.g006
The present study was undertaken to test the immunogenicity, as well as efficacy, of VMP001 in *Aotus* monkeys. We immunized monkeys with two different doses of antigen formulated in Montanide ISA 720 and CpG 10104. Montanide ISA 720 is a water-in-oil emulsion constituted of a nonmineral metabolizable oil and a mannide monooleate surfactant [20]. CpG 10104 is a B-class 24-mer synthetic oligonucleotide with a fully phosphorothioate backbone containing 5 CpG motifs (Coley Pharma). These unmethylated CpG DNA motifs are recognized by mammalian TLR9 and are known to activate dendritic cells, macrophages and B cells [21]. Both Montanide ISA 720 and CpG have been used in clinical studies in humans with malaria antigens (www.clinicaltrials.gov) and thus, have a possible path forward for the clinical evaluation of vaccine candidates. Therefore, we chose to evaluate our vaccine in the presence of these adjuvants to take advantage of their synergistic roles in inducing a functionally-relevant immune response. Due to the possible effect of the innate immune responses induced by this combination of adjuvants on the outcome of a parasite challenge, we included a control arm in which the monkeys were injected with the adjuvant formulated with an unrelated *P. falciparum* antigen that does not exist in *P. vivax*. The final vaccine efficacy was estimated by comparing it to the outcome of the control group. Due to the fact that 25% of the control monkeys did not become parasitemic, our calculated vaccine efficacy for both the low and high dose groups singly, and in combination, following the primary challenge was 66.7%, with a total of 12 out of 16 immunized monkeys remaining free of blood stage parasites. Both the low- and high-dose groups induced robust immune responses to the whole recombinant protein (VMP001), as well as the N-term, repeat- and C-term regions of the protein. However, only anti-repeat antibodies showed a statistical association with protection. The twelve protected monkeys had statistically significant antibody response that was 4.3-fold higher compared to the response in the non-protected monkeys. In contrast, the protected and non-protected monkeys had differences of 1.7-fold, or less, in anti-VMP001, N- and C-term antibody titers. While similar comparisons with the various components (the entire immunogen, or the C-term region) have not been published for RTS,S the only subunit malaria vaccine to show consistent immune responses to the whole recombinant protein (VMP001), as well as the N-term, repeat- and C-term regions of the protein. However, only anti-repeat antibodies showed a statistical association with protection. The twelve protected monkeys had statistically significant antibody response that was 4.3-fold higher compared to the response in the non-protected monkeys. In contrast, the protected and non-protected monkeys had differences of 1.7-fold, or less, in anti-VMP001, N- and C-term antibody titers. While similar comparisons with the various components (the entire immunogen, or the C-term region) have not been published for RTS,S the only subunit malaria vaccine to show consistent immune responses to the whole recombinant protein (VMP001), as well as the N-term, repeat- and C-term regions of the protein. However, only anti-repeat antibodies showed a statistical association with protection. The twelve protected monkeys had statistically significant antibody response that was 4.3-fold higher compared to the response in the non-protected monkeys. In contrast, the protected and non-protected monkeys had differences of 1.7-fold, or less, in anti-VMP001, N- and C-term antibody titers. While similar comparisons with the various components (the entire immunogen, or the C-term region) have not been published for RTS,S the only subunit malaria vaccine to show consistent inoculation of nonhuman primate models with the *P. vivax* Brazil VII strain in *A. nancymae*—can help serve as a benchmark for down-selection of adjuvant formulations in future studies with the current vaccine antigen, or while designing new antigens to serve as a vaccine.

Acknowledgments

AY would like to thank Dr. Ousman Jobe, WRAIR, for insightful discussions and suggestions that helped shape the manuscript; as well as Parul Dayal, Saule Nurmakambetova and members of the Malaria Serology lab (WRAIR) for their help with some of the ELISAs. Many thanks to Liz Duncan and Maria Belmonte for their help with converting figures to print-ready format. Authors would also like to thank the vet med staff (CDC) for their help during the study.

Disclaimer: The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of either the Department of the Army, the Department of Defense, the Department of Health and Human Services or the US government.

Author Contributions

Conceived and designed the experiments: AY CFO JWBJ. Performed the experiments: CEH JSS DN TW WEC JWB. Analyzed the data: AY JWBJ. Contributed reagents/materials/analysis tools: AY JWBJ. Wrote the paper: AY JWBJ.

References

1. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, et al. (2012) A long neglected world malaria map. Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 6: e10114.
2. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, et al. (2007) Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77: 79–87.
3. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI (2013) G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol 81: 133–201.
4. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, et al. (2013) PRF1 deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol 81: 133–201.
5. Baird JK (2013) Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev 26: 36–57.
6. Hollingdale MR, Collins WE, Campbell CC, Schwartz AL (1985) In vitro culture of two populations (dividing and nondividing) of exoerythrocytic parasites of Plasmodium vivax. Am J Trop Med Hyg 36: 1381–1382.
7. Yadav A, Sattabongkot J, Washington MA, Ware LA, Majum V, et al. (2007) A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect Immun 75: 1177–1185.
8. Bell BA, Wood JP, Bansal R, Ragab H, Cargo J. 3rd, et al. (2009) Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax. Vaccine 27: 1448–1453.
9. Barr PJ, Gibson HL, Enca E, Arnott DE, Hollingdale MR, et al. (1997) Expression in yeast of a Plasmodium vivax antigen of potential use in a human malaria vaccine. J Exp Med 185: 1169–1176.
10. Collins WE, Nusemire华盛顿 RCS, Ballou RW, Ruebush TK, 2nd, Nardin EH, et al. (1989) Immunization of Saimiri sciureus boliviensis with recombinant vaccines based on the circumsporozoite protein of Plasmodium vivax. Am J Trop Med Hyg 40: 455–464.
11. Yang C, Collins WE, Xiao L, Saenkhou AM, Reed RG, et al. (1995) Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin. Vaccine 15: 377–386.
12. Collins WE, Sullivan JS, Morris CL, Galland GG, Jue DL, et al. (1997) Protective immunity induced in squirrel monkeys with a multiple antigen construct against the circumsporozoite protein of Plasmodium vivax. Am J Trop Med Hyg 56: 200–210.

13. Herrera S, De Plata G, Gonzalez M, Perlaza BL, Bettens F, et al. (1997) Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing P. vivax CS epitopes in Aotus monkeys. Parasite Immunol 19: 161–170.

14. Herrera S, Botello A, Perlaza BL, Valencia AZ, Cifuentes C, et al. (2004) Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. Int J Parasitol 34: 1535–1546.

15. Hillier CJ, Ware LA, Barbosa A, Angov E, Lyon JA, et al. (2005) Process development and analysis of five-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infect Immun 73: 2109–2115.

16. Kester KE, Cummings JF, Ockenhouse CF, Nielsen R, Hall BT, et al. (2008) Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 26: 2191–2202.

17. Reyes-Sandoval A, Bachmann MF (2013) Plasmodium vivax malaria vaccines: Why are we where we are? Hum Vaccin Immunother 9: 2558–2563.

18. Lumsden JM, Pichyangkul S, Srihirunpanakul U, Yongvanitchit K, Limsalakpetch A, et al. (2011) Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. Infect Immun 79: 3492–3500.

19. Vanloubbeeck Y, Pichyangkul S, Bayat B, Yongvanitchit K, Bennett JW, et al. (2013) Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques. Vaccine 31: 6216–6224.

20. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Game V (2002) Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 1: 111–118.

21. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373–384.

22. Charoenvit Y, Collins WE, Jones TR, Millet P, Yuan L, et al. (1991) Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science 251: 668–671.